Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP & CCO

SVP, Human Resources

EVP & Gen. Counsel & Secy.

Chairman, CEO and President

EVP, Operations

EVP & Chief Technology Officer

VP, Finance & CAO

EVP, Global Commercial Ops

EVP & CFO

SVP, Business Development

EVP, R&D, & Chief Sci. Officer

EVP, Research and Development

EVP, Gen. Counsel & Secy.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃƒÂ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	SVP & CCO
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Human Resources
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	EVP & Gen. Counsel & Secy.
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	Chairman, CEO and President
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Operations
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	EVP & Chief Technology Officer
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	VP, Finance & CAO
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Global Commercial Ops
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	EVP & CFO
2024-03-18	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Business Development
2024-03-06	Premium	acquired	Premium	Premium	Premium	EVP, Global Commercial Ops
2024-03-06	Premium	acquired	Premium	Premium	Premium	EVP & Chief Technology Officer
2024-03-06	Premium	acquired	Premium	Premium	Premium	Chairman, CEO and President
2024-03-06	Premium	acquired	Premium	Premium	Premium	SVP & CCO
2024-03-06	Premium	acquired	Premium	Premium	Premium	EVP, Operations
2024-03-06	Premium	acquired	Premium	Premium	Premium	SVP, Human Resources
2024-03-06	Premium	acquired	Premium	Premium	Premium	VP, Finance & CAO
2024-03-06	Premium	acquired	Premium	Premium	Premium	SVP, Business Development
2024-03-06	Premium	acquired	Premium	Premium	Premium	EVP & CFO
2024-03-06	Premium	acquired	Premium	Premium	Premium	EVP & Gen. Counsel & Secy.
2024-02-09	Premium	acquired	Premium	Premium	Premium	EVP, R&D, & Chief Sci. Officer
2023-12-04	Premium	sold	Premium	Premium	Premium	SVP & CCO
2023-11-28	Premium	gifted	Premium	Premium	Premium	EVP, Research and Development
2023-11-08	Premium	sold	Premium	Premium	Premium	EVP, Gen. Counsel & Secy.
2023-11-05	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Business Development

AMGN - Amgen Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for AMGN